Stelara Approval Expands; Good News in Celiac Disease; Curcumin for Adenomas
(MedPage Today) -- The FDA said it expanded approval of the interleukin (IL)-12/23 antagonist ustekinumab (Stelara) to include treatment of moderately to severely active ulcerative colitis in children as young as 2 years. Using pooled data from...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.